BSLN
vs
S
Swiss Market Index
BSLN
Over the past 12 months, BSLN has significantly outperformed Swiss Market Index, delivering a return of +33% compared to the Swiss Market Index's +10% growth.
Stocks Performance
BSLN vs Swiss Market Index
Performance Gap
BSLN vs Swiss Market Index
Performance By Year
BSLN vs Swiss Market Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.